TON - February 2021 Vol 14, No 1

From The Editor February 2021
In this issue of The Oncology Nurse-APN/PA (TON), we provide our readers with a variety of articles aimed at helping them stay informed on important issues facing nurses, navigators, and advanced practice providers. Read More ›

Penn Medicine’s Abramson Cancer Center (ACC) is comprised of 6 hospitals and many facilities located in the tristate area of Pennsylvania, New Jersey, and Delaware. Read More ›

When it comes to gathering and assessing social determinants of health (SDoH) as part of a medically appropriate history and examination, it is necessary to employ 5 key strategies, said Allysceaeioun D. Britt, PhD, MPH, Interim Vice President, Office of Faculty Affairs and Development, Meharry Medical College, Nashville, TN, in a presentation during the virtual 2020 Healthcare Administration Alliance Conference. Read More ›


The Importance of Collaboration Between Community Health Workers and Clinical Care Teams
Helping patients with cancer achieve optimal health status can present special challenges when their basic needs such as food security, housing, and transportation are not being met. Read More ›

A post-hoc analysis of a pivotal clinical trial showed that belantamab mafodotin-blmf (Blenrep), a first-in-class antibody–drug conjugate targeting B-cell maturation antigen, induced deep and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. Read More ›

Financial toxicity can have a negative effect on outcomes for patients with cancer. However, findings from a recent pilot study revealed that a comprehensive intervention focused on the financial aspects of care significantly improved quality of life for patients with hematologic malignancies. Read More ›

Approximately two-thirds of patients with chronic-phase chronic myeloid leukemia (CML) achieved a major cytogenetic response to the novel oral BCR-ABL1 tyrosine kinase inhibitor (TKI) vodobatinib, regardless of whether they had received previous treatment with ponatinib (Iclusig), according to findings from a recent phase 1 clinical trial. Read More ›

In April 2020, the FDA granted accelerated approval to pemigatinib (Pemazyre), the first targeted therapy for cholangiocarcinoma (CCA). The FGFR inhibitor was approved for adults with CCA and FGFR2 fusion. Read More ›

Targeted therapy has improved survival for patients with cancer across a broad spectrum of disease sites, but until recently, progress has been slow in applying the use of targeted therapies in the treatment of patients with cholangiocarcinoma (CCA). Read More ›

Page 1 of 2


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: